TY - JOUR
T1 - MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis
AU - Lemberger, Moran
AU - Loewenstein, Shelly
AU - Lubezky, Nir
AU - Nizri, Eran
AU - Pasmanik-Chor, Metsada
AU - Barazovsky, Eli
AU - Klausner, Joseph M.
AU - Lahat, Guy
N1 - Publisher Copyright:
© 2019 Impact Journals LLC. All Rights Reserved.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Lymph node (LN) metastasis occurs frequently in pancreatic ductal adenocarcinoma (PDAC), representing an advanced disease stage and independently predicting patient survival. Current nodal staging is inadequate preoperatively and even less so postoperatively, and molecular biomarkers are needed to improve prognostication and selection of therapy. Recent data have suggested important roles of miRNAs in PDAC tumorigenesis and progression. The aim of the present study was to identify miRNA expression signature for nodal spread in PDAC patients. Using PDAC human tissue specimens, we identified 39 miRNAs which were differently expressed in LN positive compared to LN negative PDAC samples. Of them, six miRNAs have been reported to play a role in cancer invasion and metastasis. A high versus low six- miRNA signature score was predictive of LN metastasis in the PDAC validation cohort. We demonstrated a similar expression pattern of four out of the six miRNAs in the plasma of PDAC patients. The results of our in-vitro studies revealed that miR- 141 and miR-720 are involved in the process of epithelial to mesenchymal-transition in PDAC. These miRNAs significantly inhibited in vitro proliferation, migration and invasion of PDAC cells as evidence by gain- and loss- of function studies, specifically, via ZEB-1 and TWIST1 transcription factors, as well as through the activation of the MAP4K4/JNK signaling pathway.
AB - Lymph node (LN) metastasis occurs frequently in pancreatic ductal adenocarcinoma (PDAC), representing an advanced disease stage and independently predicting patient survival. Current nodal staging is inadequate preoperatively and even less so postoperatively, and molecular biomarkers are needed to improve prognostication and selection of therapy. Recent data have suggested important roles of miRNAs in PDAC tumorigenesis and progression. The aim of the present study was to identify miRNA expression signature for nodal spread in PDAC patients. Using PDAC human tissue specimens, we identified 39 miRNAs which were differently expressed in LN positive compared to LN negative PDAC samples. Of them, six miRNAs have been reported to play a role in cancer invasion and metastasis. A high versus low six- miRNA signature score was predictive of LN metastasis in the PDAC validation cohort. We demonstrated a similar expression pattern of four out of the six miRNAs in the plasma of PDAC patients. The results of our in-vitro studies revealed that miR- 141 and miR-720 are involved in the process of epithelial to mesenchymal-transition in PDAC. These miRNAs significantly inhibited in vitro proliferation, migration and invasion of PDAC cells as evidence by gain- and loss- of function studies, specifically, via ZEB-1 and TWIST1 transcription factors, as well as through the activation of the MAP4K4/JNK signaling pathway.
KW - Epithelial-to-mesenchymal transition (EMT)
KW - Invasion
KW - Lymph node metastasis
KW - MicroRNA
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85064987369&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.26804
DO - 10.18632/oncotarget.26804
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85064987369
SN - 1949-2553
VL - 10
SP - 2644
EP - 2656
JO - Oncotarget
JF - Oncotarget
IS - 27
ER -